Home>Topics>Companies>St. Jude Medical

St. Jude Medical STJ

  1. All
  2. Commentary
  3. Headlines
    1. St . Jude Medical Sees Solid 3Q With More to Come From New Products

      Commentary

      Wed, 15 Oct 2014

      St . Jude Medical 's third-quarter results were largely ..... neuromodulation products, wide-moat St . Jude saw quarterly top-line growth of 3 ..... double-digit growth seen historically, St . Jude has been making steady progress recovering

    2. CR Bard Bolsters Narrow Moat With Technology That Appeals to Hospitals Seeking Efficiencies

      Commentary

      Mon, 25 Aug 2014

      physicians have less influence on brand decisions compared with highly engineered, implantable devices. Unlike St . Jude Medical and Zimmer's devices, Bard's products are generally more vulnerable to pricing pressure. However, Bard's

    3. Edwards Lifesciences Posts Strong 2Q on New Launches; We've Raised Our Fair Value Estimate

      Commentary

      Wed, 30 Jul 2014

      this arena. While we had cautiously anticipated rising competition now that Medtronic has entered the U.S. and St . Jude Medical and Boston Scientific have launched in Europe, Edwards showed its own strength in both markets with its rollout

    4. Boston Scientific Exceeds Our Expectations in the Second Quarter

      Commentary

      Thu, 24 Jul 2014

      ICD, Boston racked up 4% year-over-year ICD growth--the strongest seen in 12 quarters. Although peers St . Jude Medical and Medtronic have both launched leadless pacemakers, Boston still offers the only leadless ICD. While Boston

    5. St . Jude Delivers Solid 2Q Results

      Commentary

      Wed, 16 Jul 2014

      St . Jude Medical posted solid second-quarter performance ..... estimate in place. We were heartened to see St . Jude 's sales of implantable cardioverter defibrillators ..... recently declined in the low single digits. St . Jude 's recent acquisition of Cardiomems

    6. Tides Turn for These Orthopedic Firms

      Headlines

      Mon, 30 Jun 2014

      viewpoint. With switching costs lower in cardiac rhythm management devices, the three CRM makers--Medtronic, St . Jude Medical , and Boston Scientific--derive much of their moatiness from efficient scale and operate in a rational oligopoly

    7. St . Jude Aims to Bolster Growth with New Products

      Commentary

      Wed, 16 Apr 2014

      St . Jude Medical released first-quarter results that ..... material effect on our $59 valuation. St . Jude has been focused and diligent about extending ..... approval in the 2014-15 time frame. St . Jude 's consistent innovation bolsters the

    8. No Surprises in Medtronic's Fiscal Third Quarter

      Headlines

      Wed, 19 Feb 2014

      quarters, competition from St . Jude Medical STJ and Boston Scientific BSX has ..... bowed out of the market, but St . Jude Medical remains committed to commercializing ..... primarily with Boston Scientific and St . Jude Medical . The competitors may trade

    9. St . Jude Medical Posts Strong Fourth Quarter, Spurring a Boost to Our Fair Value Estimate

      Commentary

      Thu, 23 Jan 2014

      St . Jude Medical 's fourth-quarter results were stronger ..... estimates of ICD growth. We are leaving St . Jude 's wide moat and stable trend in place ..... intrigued by management's suggestion that St . Jude would exercise its option to purchase

    10. Medtronic Sees Disappointing Trial Data for Its Renal Denervation Technology

      Commentary

      Thu, 9 Jan 2014

      technology, or whether it holds broader implications for all the other firms pursuing the same treatment, including St . Jude Medical , Covidien, and Boston Scientific. The pool of patients with drug-resistant hypertension remains an attractive

    « Prev12345Next »
    Content Partners